City

Copenhagen (1)

Gliwice (1)

Krakow (1)

Poznan (1)

Shanghai (1)

Warszawa (1)

Wroclaw (1)

Condition

Response Rate (3)

Adverse Event (1)

Chronic Graft-versus-host-disease (1)

Chronic Lymphocytic Leukemia (1)

Mantle Cell Lymphoma (1)

Overall Status

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

n/a (1)

Sponsor

Polish Lymphoma Research Group (1)

Shanghai Jiao Tong University School of Medicine (1)

University of Southern Denmark (1)

Collaborator

AstraZeneca (1)

Intervention

acalabrutinib 2x100 mg oral capsule + allosct (1)

decitabine (1)

targeted cover letter (1)

Study Documents

Intervention Type

drug (2)

behavioral (1)

Funder Type

Other (3)

Study Type

Interventional (3)

response rate

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma Trial in Poland (Acalabrutinib 2x100 MG

Recruiting

Chronic Lymphocytic Leukemia
+4 more

Acalabrutinib 2x100 MG Oral Capsule + alloSCT

Warszawa, Mazowieckie, Poland
+5 more

Dec 23, 2021

Response Rate Trial in Shanghai (Decitabine)

Completed

Response Rate

Decitabine

Shanghai, Shanghai, China

Blood & Marrow Transplantation Center, RuiJin Hospital

May 19, 2021

Response Rate Trial in Copenhagen (Targeted cover letter)

Completed

Response Rate

Targeted cover letter

Copenhagen, Denmark

National Institute of Public health, University of Southern Denm

Mar 23, 2020